Agrawal YN, Fernandez-Martinez A, Gil-Gil M, Zielinski C, Ruiz-Borrego M, Ciruelos EM, Munoz M, Margeli M, Bermejo B, Anton A, Kahan Z, Csoszi T, Alonso-Romero JL, Garcia-Saenz JA, Sanchez-Rovira P, Alvarez E, Chacon JI, Gonzalez-Santiago S, Rodriguez CA, Servitja S, Pfefferle AD, Herranz J, Liu Y, Carey LA, Romero-Camarero I, Caballero R, Guerrero-Zotano A, Perou CM, Martin M. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. JCO Precis Oncol. 2025 Jul;9:e2400937. doi: 10.1200/PO-24-00937. Epub 2025 Jul 9. PubMed PMID: 40632974; PubMed Central PMCID: PMC12261110.
AÑO: 2025; IF: 5.3